ecrin-mdr-crcClinical2005Colorectal CarcinomaColorectal NeoplasmsColorectal CarcinomaColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2020680Portugal7CetuximabECRIN MDRNot providedfalseXELOX Plus Cetuximab as First-Line Therapy in Patients With Metastatic Colorectal CancerThe first phase II trial with cetuximab and FOLFOX, as 1st line therapy for MCRC, presented at ASCO 2004, showed a 81% response rate, with no unexpected toxicities for the combination. This study is aimed at establishing the efficacy and safety of the combination cetuximab/XELOX as first line therapy in patients with MCRC.2005-07-152020680NCT00215722